Abstract: Materials and methods for identifying inhibitors of protease activity are provided herein. For example, this document provides materials and methods that can be used to identify inhibitors of a protease (e.g., SARS-CoV-2 Mpro).

Abstract: Real-time systems for monitoring base editing in living cells, including base editing by APOBEC-Cas9 fusions, is provided herein.

Abstract: Materials and methods for using modified Cas9-APOBEC fusion polypeptides for targeted modification of specific DNA sequences are provided herein.

Abstract: This document relates to materials and methods for DNA base editing with reduced off-target mutations. In particular, this document relates to materials and methods that include using fusion proteins containing a Cas9 molecule and an APOBEC-interacting molecule to achieve specific DNA edits with reduced levels of off-target edits.

Abstract: Hybridoma cell lines produce monoclonal antibodies that specifically bind to an APOBEC3 protein. The antibodies can be used in various methods. In some aspects, an anti-APOBEC3 antibody may be immobilized to a substrate. In another aspect, this disclosure provides a vector that includes a nucleic acid sequence encoding antibody produced by a hybridoma cell line that produces an antibody that specifically binds to an APOBEC3 protein.

Abstract: In one aspect, a method of treating a subject having or at risk of having a tumor generally includes administering to the subject an amount of a PKC-NF?B axis inhibitor effective to ameliorate at least one symptom or clinical sign of the tumor. In another aspect, a method of treating a subject having a tumor generally includes confirming that APOBEC3B is present in cells of the tumor and administering to the subject an amount of a PKC-NF?B axis inhibitor effective to decrease APOBEC3B in the cells of the tumor.

Abstract: Materials and methods for using modified APOBEC polypeptides for modification of DNA sequences are provided herein.

Abstract: A method of treating a subject having a tumor generally includes administering to the subject an amount of an APOBEC3 upregulator effective to increase mutagenesis in cells of the tumor.

Abstract: This disclosure describes a kit for determining the level of APOBEC3 in a sample of a subject, and a method for making an anti-APOBEC3 antibody/APOBEC3 complex. This disclosure further describes methods of determining a prognosis of a subject having a cancer using APOBEC3 expression and, in some instances, providing treatment based on the prognosis.

Abstract: Real-time systems for monitoring base editing in living cells, including base editing by APOBEC-Cas9 fusions, is provided herein.

Abstract: In one aspect, a method of treating a subject having or at risk of having a tumor generally includes administering to the subject an amount of a PKC-NFkB axis inhibitor effective to ameliorate at least one symptom or clinical PMA sign of the tumor. In another aspect, a method of treating a subject having a tumor generally includes confirming that APOBEC3B is present in cells of the tumor and administering to the subject an amount of a PKC-NFkB axis inhibitor effective to decrease APOBEC3B in the cells of the tumor.

Abstract: Hybridoma cell lines produce monoclonal antibodies that specifically bind to an APOBEC3 protein. The antibodies can be used in various methods. In some aspects, an anti-APOBEC3 antibody may be immobilized to a substrate. In another aspect, this disclosure provides a vector that includes a nucleic acid sequence encoding antibody produced by a hybridoma cell line that produces an antibody that specifically binds to an APOBEC3 protein.

Abstract: Materials and methods for using modified Cas9-APOBEC fusion polypeptides for targeted modification of specific DNA sequences are provided herein.

Abstract: Transgenic pigs that express one or more non-porcine cytosine deaminases are described as well as methods of making and using such pigs.

Abstract: Compounds and methods are provided for enhancing or boosting the transfection rate or efficiency of mammalian cells by foreign DNA, such as bacterial plasmid DNA. Compounds, including natural products and inventive synthetic compounds can increase the effectiveness of uptake and incorporation of foreign DNA by mammalian cells, such as human cells, by suppression of DNA cytosine deamination, which is believed to be a mechanism by which these cells eliminate foreign DNA. Inhibition of the cytosine deaminase enzymes by compounds as described herein serves to provide more effective transfection of eukaryotic cells by plasmids including engineered gene sequences. Transfection can be used to study cellular processes, or to cure genetic diseases in human patients. The inventive materials and methods increase the efficiency and effectiveness of such transfection techniques.

Abstract: This disclosure describes APOBEC3B as a biomarker for certain cancers such as, for example, breast cancer. This disclosure therefore describes methods for detecting APOBEC3B in a biological sample. The methods generally include measuring expression of APOBEC3B in a biological sample obtained from a patient and identifying the patient as having or at risk for having cancer if the measured expression of APOBEC3B is greater than a predetermined reference level of expression. This disclosure also describes isolated polynucleotides that may be used as reagents in methods for detecting and/or measuring APOBEC3B expression.

Abstract: Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.

Abstract: The document provides modified cytosine deaminases with increased solubility and high levels of DNA cytosine deaminase activity.

Abstract: Transgenic pigs that express one or more non-porcine cytosine deaminases are described as well as methods of making and using such pigs.

Abstract: The document provides modified cytosine deaminases with increased solubility and high levels of DNA cytosine deaminase activity.